Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Pinkawa, Michael ^a   Piroth, Marc D ^a   Holy, Richard ^a   Klotz, Jens ^a   Djukic, Victoria ^a   Escobar Corral, Nuria ^a   Caffaro, Mariana ^a   Winz, Oliver H ^a   Krohn, Thomas ^a   Mottaghy, Felix M ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Choline pet; Intensity modulated radiotherapy; Prostate cancer; Quality of life; Simultaneous integrated boost

Indexed keywords

FLUORINE 18; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUOROCHOLINE;

ARTICLE; CANCER PATIENT; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; INTESTINE FUNCTION; MALE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; SIMULTANEOUS INTEGRATED BOOST; URINARY TRACT FUNCTION; AGED; COMPUTER ASSISTED RADIOTHERAPY; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE TUMOR; QUESTIONNAIRE; RADIATION RESPONSE;

AGED; AGED, 80 AND OVER; CHOLINE; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84856253220     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-14     Document Type: Article

References (24)

1. Viani GA, Stefano EJ, Alfonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009, 74:1405-1418. 10.1016/j.ijrobp.2008.10.091, 19616743.
2. Pinkawa M, Piroth MD, Fischedick K, Nussen S, Klotz J, Holy R, Eble MJ. Self-assessed bowel toxicity after external beam radiotherapy for prostate cancer--predictive factors on irritative symptoms, incontinence and rectal bleeding. Radiat Oncol 2009, 4:36. 10.1186/1748-717X-4-36, 2753361, 19772568.
3. Pinkawa M, Holy R, Piroth MD, Fischedick K, Schaar S, Székely-Orbànm Eble MJ. Consequential late effets after radiotherapy for prostate cancer - a prospective longitudianl quality of life study. Radiat Oncol 2010, 5:27. 10.1186/1748-717X-5-27, 2857853, 20377874.
4. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, Manfredi R, Dinapoli N, Digesu C, Smaniotto D. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002, 53:595-599. 10.1016/S0360-3016(02)02795-5, 12062602.
5. Chen ME, Johnston DA, Tang K, Babaian RJ, Troncoso P. Detailed mapping of prostate carcinoma foci: biopsy strategy implications. Cancer 2000, 89:1800-1809. 10.1002/1097-0142(20001015)89:8<1800::AID-CNCR21>3.0.CO;2-D, 11042576.
6. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, Pettinato C, Salizzoni E, Monetti N, Franchi R, Fanti S. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005, 46:1642-1649.
7. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006, 47:262-269.
8. Pinkawa M, Attieh C, Piroth MD, Holy R, Nussen S, Klotz J, Hawickhorst R, Schäfer W, Eble MJ. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol 2009, 93:213-219. 10.1016/j.radonc.2009.07.014, 19717197.
9. Pinkawa M, Pursch-Lee M, Asadpour B, Gagel B, Piroth MD, Klotz J, Nussen S, Eble MJ. Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction motion. Strahlenther Onkol 2008, 184:679-685. 10.1007/s00066-008-1902-7, 19107350.
10. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys 1991, 21:123-135.
11. Emami B, Lyman JT, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109-122.
12. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (epic) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905. 10.1016/S0090-4295(00)00858-X, 11113727.
13. Volz-Sidiropoulou E, Pinkawa M, Fischedick K, Jakse G, Gauggel S, Eble MJ. Factor analysis of the Expanded Prostate Cancer Index Composite (EPIC) in a patient group after primary (external beam radiotherapy and permanent iodine-125 brachytherapy) and postoperative radiotherapy for prostate cancer. Curr Urol 2008, 2:122-129.
14. Pinkawa M, Holy R, Piroth DM, Klotz J, Pfister D, Heidenreich A, Eble MJ. Interpreting the clinical significance of quality of life score changes after radiotherapy for localized prostate cancer. Curr Urol 2011, 5:137-144.
15. Pinkawa M, Eble MJ, Mottaghy FM. PET and PET/CT in radiation treatment planning for prostate cancer. Expert Rev Anticancer Ther 2011, 7:1035-1041.
16. Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, De Meerleer G. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion. Int J Radiat Oncol Biol Phys 2008, 72:799-807. 10.1016/j.ijrobp.2008.01.040, 18407430.
17. Rinnab L, Mottaghy FM, Blumstein NM, Resje SN, Hautmann RE, Hohl K, Möller P, Wiegel T, Kuefer R, Gschwend JE. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007, 100:786-93. 10.1111/j.1464-410X.2007.07083.x, 17822459.
18. Emonds KM, Swinnen JV, Mortelmanns L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 2009, 48:193-199. 10.1016/j.ymeth.2009.03.021, 19362147.
19. Wang J, Bai S, Chen N, Xu F, Jiang X, Li Y, Xu Q, Shen Y, Zhang H, Gong Y, Zhong R, Jiang Q. The clinical feasibility of online cone beam computer tomography-guided intensity-modulated radiotherapy for nasopharyngeal cancer. Radiother Oncol 2009, 90:221-227. 10.1016/j.radonc.2008.08.017, 18930327.
20. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Wárlám-Rodenhuis CC, Pierart M, Collette L. Impact of higher radiation dose on local control and survival after breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007, 25:3259-3265. 10.1200/JCO.2007.11.4991, 17577015.
21. Pinkawa M, Holy R, Piroth DM, Klotz J, Nussen S, Krohn T, Mottaghy FM, Weibrecht M, Eble MJ. Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost. Strahlenther Onkol 2011, 186:600-606.
22. Sutinen E, Nurmi M, Roivainen A, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, Minn H. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004, 31:317-324. 10.1007/s00259-003-1377-9, 14628097.
23. Piert M, Park H, Khan A, Siddiqui J, Hussain H, Chenevert T, Wood D, Johnson T, Shah RB, Meyer C. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques. J Nucl Med 2009, 50:1585-1593. 10.2967/jnumed.109.063396, 2837847, 19759109.
24. De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, De Neve W. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 2005, 75:325-333. 10.1016/j.radonc.2005.04.014, 15967524.